Skip to content
Brand AI

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2024

    Fined RMB 800,000 for underpaying tax due to improper R&D expense deductions

    In its Hong Kong IPO filing, Jingxin Pharmaceutical disclosed that in December 2024 it was fined RMB 800,000 by tax authorities for improper R&D expense deductions that underpaid corporate income tax by about RMB 1 million, and for failing to withhold and remit about RMB 400,000 in personal income tax in 2021 and 2023. Fine.

    Source